Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Forecast for the Multiple Myeloma Market Growth in 2025?

The size of the multiple myeloma market has exhibited robust growth in the past few years. The market, valued at $26.07 billion in 2024, is projected to expand to $28.15 billion in 2025, with a compound annual growth rate (CAGR) of 8.0%. Factors such as advancements in diagnostic methodologies, the advent of stem cell transplantation, the availability of high-quality healthcare services, the adoption of precision medicine, and the introduction of patient-centric care models have driven the growth during the historical period.

What Is the Forecast for the Multiple Myeloma Market Size Through 2029?

The market size of multiple myeloma is anticipated to witness robust expansion in the upcoming years. It’s projected to escalate to $38.39 billion in 2029, with a compound annual growth rate (CAGR) of 8.1%. This surge during the forecast period is attributable to the incorporation of health technology, uptake of telemedicine services, individualized vaccine therapies, and digital health platforms aimed at educating patients. The leading trends during this period will be the progress in targeted therapies, the creation of novel drugs, advancements in immunotherapy, the development of innovative biomarkers, and the amalgamation of artificial intelligence.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12163&type=smp

What are the Key Market Players in Multiple Myeloma Market and How They’re Evolving?

Major companies operating in the multiple myeloma market include Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Amgen Inc., Janssen Global Services LLC, Celgene Corporation, Mylan N.V., Biogen Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., CRISPR Therapeutics AG, Karyopharm Therapeutics Inc., Fate Therapeutics Inc., Atara Biotherapeutics Inc., Allogene Therapeutics Inc., C4 Therapeutics Inc., Adaptimmune Therapeutics plc, Precision Biosciences Inc.

What Are the Primary Growth Drivers in the Multiple Myeloma Market?

The multiple myeloma market is poised for growth due to the rising incidence of multiple myeloma. Multiple myeloma, a type of cancer that develops in plasma cells which are a kind of white blood cell, is escalating owing to factors such as aging, genetics, obesity, exposure to radiation, and other health conditions. The aim of treating multiple myeloma is to halt its progression and alleviate symptoms. As stated by the American Cancer Society, a voluntary health organization in the US, the count of novel multiple myeloma cases rose to 35,730 in 2023, up from 34,470 in 2022, further reinforcing the market expansion driven by the increased prevalence of multiple myeloma.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12163&type=smp

What Are the Leading Segments in the Global Multiple Myeloma Industry?

The multiple myeloma market covered in this report is segmented –

1) By Treatment: Medications, Radiation Therapy, Stem Cell Transplant, Other Treatments

2) By Diagnosis: Blood Tests, Bone Marrow Biopsy, Urine Tests, Imaging Tests

3) By Disease Type: Active Multiple Myeloma, Smoldering Multiple Myeloma

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Channels

Subsegments:

1) By Medications: Immunomodulatory Drugs (IMiDs), Proteasome Inhibitors, Monoclonal Antibodies, Corticosteroids, Chemotherapy Agents

2) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Radioisotope Therapy

3) By Stem Cell Transplant: Autologous Stem Cell Transplant (ASCT), Allogeneic Stem Cell Transplant

4) By Other Treatments: Supportive Care, Clinical Trials And Experimental Therapies

What Are the Key Market Trends in the Multiple Myeloma Industry?

One key trend that is gaining traction in the multiple myeloma market is product innovation. To maintain their market presence, dominant companies in this sector are focusing on producing innovative products. For example, in October 2022, Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company based in Belgium, was granted approval for TECVAYLI (teclistamab-cqyv), the first of its kind bispecific T-cell engager antibody, from the US Food and Drug Administration (FDA). This drug is intended for the treatment of adult multiple myeloma patients who have undergone at least four previous lines of therapy, which includes proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies targeting CD38. The drug functions by aiming at the B-cell maturation antigen (BCMA), found on the surface of some healthy B-lineage cells, and the CD3 receptor present on T-cells and multiple myeloma cells’ surfaces.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/multiple-myeloma-global-market-report

What Is the Regional Outlook for the Multiple Myeloma Market?

North America was the largest region in the multiple myeloma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple myeloma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12163

This Report Delivers Insight On:

1. How big is the multiple myeloma market, and how is it changing globally?

2. Who are the major companies in the multiple myeloma market, and how are they performing?

3. What are the key opportunities and risks in the multiple myeloma market right now?

4. Which products or customer segments are growing the most in the multiple myeloma market?

5. What factors are helping or slowing down the growth of the multiple myeloma market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model